AMEX To Trade Options On Biocryst Pharmaceuticals

NEW YORK, Oct. 25 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Wednesday, October 26, 2005 on the Nasdaq Stock Market listed stock of BioCryst Pharmaceuticals, Inc. .

BioCryst Pharmaceuticals, Inc. will open with position limits of 25,000,000 shares. The options will trade on the March expiration cycle. The specialist will be Kellogg Capital Group, LLC.

BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.

For more information on any Amex-listed company, please visit http://www.amex.com.

The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 169 ETFs. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com.

CONTACT: Mary Chung of American Stock Exchange, +1-212-306-1641,mary.chung@amex.com

Web site: http://www.amex.com/